Lundqvist J, Kastäng F, Kobelt G, Jönsson B
i3/Innovus, Stockholm, Sweden.
Eur J Health Econ. 2008 Jan;8 Suppl 2:S87-93. doi: 10.1007/s10198-007-0090-1.
As part of the study "The Burden of Rheumatoid Arthritis (RA) and Patient Access to Treatment", this paper reviews the impact on access to RA drugs of the approval processes, pricing and funding decisions and times to market (access) in different countries. In addition, an overview of health technology assessments (HTA) and the economic literature related to RA treatments is provided. The time from approval to market access ranged from immediate to over 500 days in the countries included in the study. A total of 55 HTA reports were identified, 40 of them in the period between 2002 and 2006; 29 were performed by European HTA agencies, 14 in Canada and 7 in the United States. A total of 239 economic evaluations related to RA were identified in a specialized health economic database (HEED).
作为“类风湿性关节炎（RA）负担与患者治疗可及性”研究的一部分，本文回顾了不同国家的审批流程、定价与资金决策以及上市时间（可及性）对类风湿性关节炎药物可及性的影响。此外，还概述了卫生技术评估（HTA）以及与类风湿性关节炎治疗相关的经济学文献。在该研究涵盖的国家中，从获批到上市的时间从即刻上市到超过500天不等。共识别出55份卫生技术评估报告，其中40份在2002年至2006年期间；29份由欧洲卫生技术评估机构完成，14份在加拿大，7份在美国。在一个专门的卫生经济数据库（HEED）中，共识别出239项与类风湿性关节炎相关的经济评估。
